国际医药卫生导报2023，Vol.29Issue(23)：3448-3452,5.DOI:10.3760/cma.j.issn.1007-1245.2023.23.028
卡格列净对2型糖尿病合并非酒精性脂肪性肝病患者的疗效
Efficacy of canagliflozin in patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease
摘要
Abstract
Objective Non-alcoholic fatty liver disease(NAFLD)is often accompanied by type 2 diabetes mellitus(T2DM).The current study was to evaluate the effect of canagliflozin,in addition to lifestyle modification and metformin,on T2DM patients with NAFLD.Methods This was a randomized clinical trail and 120 patients diagnosed as T2DM with NAFLD in Huizhou Third People's Hospital from October 2021 to September 2022 were randomly divided into a control group and an intervention group.In the intervention group,there were 38 males and 22 females,aged(50.5±7.0)years.In the control group,there were 37 males and 23 females,aged(51.3±8.2)years.The control group received lifestyle intervention combined with metformin 1.0 g bid,and the intervention group was additionally treated with 100 mg qd of canagliflozin in addition to the control group.Both groups were treated for 12 weeks.Serum biochemical indexes and fatty liver related indexes in the two groups were measured before and after treatment for 12 weeks,and the rates of genitourinary system infection and hypoglycemia in the two groups during treatment were also compared.Student t test,rank sum test,and x2 test were used.Results After 12 weeks of treatment,the levels of fasting blood glucose and glycosylated hemoglobin in the intervention group were lower than those in the control group[(6.7±0.5)mmol/L vs.(7.0±0.6)mmol/L,(7.0±0.5)％vs.(7.3±0.6)％],the level of triacylglycerol was lower and the level of high-density lipoprotein cholesterol was higher[1.87(0.54,2.21)mmol/L vs.2.02(0.60,2.39)mmol/L,(1.00±0.09)mmol/L vs.(0.92±0.11)mmol/L],with statistically significant differences(all P＜0.05).The plasma transaminase levels in the intervention group were lower than those in the control group,with statistically significant differences(all P＜0.05).Compared with those in the control group,the liver fibrosis indexes,liver stiffness[(7.1±3.0)kPa vs.(9.5±3.3)kPa],and liver fat content[(10.8±5.6)％vs.(13.7±5.2)％]in the intervention group were significantly lower,with statistically significant differences(all P＜0.05).There were no statistically significant differences in the incidences of adverse reactions between the two groups(all P＞0.05).Conclusion For T2DM patients with NAFLD,the addition of 12 weeks'treatment of canagliflozin can significantly improve the blood glucose and lipid metabolism disorders and can also improve NAFLD in addition to lifestyle intervention and metformin treatment.This study can provide some reference for clinicians in the treatment of T2DM patients with NAFLD.关键词
糖尿病/非酒精性脂肪性肝病/卡格列净/二甲双胍Key words
Diabetes mellitus/Non-alcoholic fatty liver disease/Canagliflozin/Metformin引用本文复制引用
蒿自睿,温影珍,蔡填,李桂平..卡格列净对2型糖尿病合并非酒精性脂肪性肝病患者的疗效[J].国际医药卫生导报,2023,29(23):3448-3452,5.基金项目
2021年惠州市科技计划项目(2021wc0106149)Huizhou Science and Technology Plan Project in 2021(2021wc0106149) （2021wc0106149）
